Orofacial Granulomatosis associated with Crohn's Disease: a multi-centre case series.

BACKGROUND Orofacial granulomatosis (OFG) is a rare syndrome that may be associated with Crohn's disease (CD). We aimed to characterise this relationship and the management options in the biologic era. METHODS This multicentre case series was supported by the European Crohn's and Colitis Organisation (ECCO), and performed as part of the Collaborative Network of Exceptionally Rare case reports (CONFER) project. Clinical data were recorded in a standardised collection form. RESULTS This report includes 28 patients with OFG associated with CD: 14 males (mean age of 32 years, ±12.4 SD) and 14 females (40.3 years, ±21.0 SD). Non-oral upper gastrointestinal tract involvement was seen in 6 cases and perianal disease in 11. The diagnosis of OFG was made prior to CD diagnosis in 2 patients, concurrently in 8 and after CD diagnosis in 18. The distribution of OFG involved the lips in 16 cases and buccal mucosa in 18. Pain was present in 25 cases, with impaired swallowing or speaking in 6. Remission was achieved in 23 patients, notably with the use of anti-TNFs in 9 patients, vedolizumab in 1, ustekinumab in 1 and thalidomide in 2. A further 5 cases were resistant to therapies including anti-TNFs. CONCLUSION OFG associated with CD may occur before, concurrently or after the diagnosis of CD. Perianal and UGI disease are common associations and there is a significant symptom burden in many. Remission can be obtained with a variety of immunosuppressive treatments, including several CD approved biologicals.

[1]  P. De Cruz,et al.  Using Ustekinumab to Treat Crohn's Disease-Related Orofacial Granulomatosis: Two Birds, One Stone. , 2020, Inflammatory bowel diseases.

[2]  E. Rey,et al.  Recurrent granulomatous cheilitis associated with Crohn’s disease successfully treated with ustekinumab: case report and literature review , 2020, Therapeutic advances in gastroenterology.

[3]  S. Vavricka,et al.  Inflammatory cutaneous lesions in inflammatory bowel disease treated with Vedolizumab or Ustekinumab: an ECCO CONFER multicentre case series. , 2019, Journal of Crohn's & colitis.

[4]  M. Escudier,et al.  The mouth in inflammatory bowel disease and aspects of orofacial granulomatosis. , 2019, Periodontology 2000.

[5]  N. Prescott,et al.  Genetic Association Analysis Reveals Differences in the Contribution of NOD2 Variants to the Clinical Phenotypes of Orofacial Granulomatosis , 2016, Inflammatory bowel diseases.

[6]  J. Sanderson,et al.  Azathioprine is effective for oral involvement in Crohn's disease but not for orofacial granulomatosis alone. , 2016, Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology.

[7]  R. Penin,et al.  Histopathological Features of Orofacial Granulomatosis , 2016, The American Journal of dermatopathology.

[8]  E. Telemo,et al.  Immunophenotype in orofacial granulomatosis with and without Crohn’s disease , 2014, Medicina oral, patologia oral y cirugia bucal.

[9]  S. Ben-Horin,et al.  Oral Crohn's disease: is it a separable disease from orofacial granulomatosis? A review. , 2012, Journal of Crohn's & colitis.

[10]  J. Sanderson,et al.  Distinguishing orofacial granulomatosis from crohn's disease: Two separate disease entities?1 , 2011, Inflammatory bowel diseases.

[11]  G. Rogler,et al.  Frequency and Risk Factors for Extraintestinal Manifestations in the Swiss Inflammatory Bowel Disease Cohort , 2011, The American Journal of Gastroenterology.

[12]  J. Sanderson,et al.  Experience with anti-TNF-α therapy for orofacial granulomatosis. , 2011, Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology.

[13]  M. Mccullough,et al.  Orofacial granulomatosis--a 20-year review. , 2009, Oral diseases.

[14]  M. Mignogna,et al.  Oral Crohn's Disease: A Favorable Clinical Response With Delayed-Release Triamcinolone Acetonide Intralesional Injections , 2013, The American Journal of Gastroenterology.

[15]  J. Sanderson,et al.  Improvement in orofacial granulomatosis on a cinnamon‐ and benzoate‐free diet , 2006, Inflammatory bowel diseases.

[16]  H. Cardoso,et al.  Successful infliximab therapy for oral Crohn's disease. , 2006, Inflammatory bowel diseases.

[17]  J. Sanderson,et al.  Oro‐Facial Granulomatosis: Crohn's Disease or a New Inflammatory Bowel Disease? , 2005, Inflammatory bowel diseases.

[18]  E. Crushell,et al.  A prospective study of the oral manifestations of Crohn's disease. , 2005, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[19]  C. Scully,et al.  Review article: orofacial granulomatosis , 2004, Alimentary pharmacology & therapeutics.

[20]  S. Porter,et al.  Thalidomide for the treatment of recalcitrant oral Crohn's disease and orofacial granulomatosis. , 2003, Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics.

[21]  D. Wray,et al.  Human leucocyte antigen typing in orofacial granulomatosis , 2000, The British journal of dermatology.

[22]  D. Wray,et al.  The role of allergy in oral mucosal diseases. , 2000, QJM : monthly journal of the Association of Physicians.

[23]  A. Dupuy,et al.  Oral Crohn disease: clinical characteristics and long-term follow-up of 9 cases. , 1999, Archives of dermatology.

[24]  H. Verspaget,et al.  Clinical aspects of Crohn's disease of the upper gastrointestinal tract: a comparison with distal Crohn's disease. , 1997, The American journal of gastroenterology.

[25]  D N Mitchell,et al.  Oro-facial granulomatosis--a clinical and pathological analysis. , 1985, The Quarterly journal of medicine.